衰弱阻碍手术:衰弱指数对手术干预及结局的影响
回顾性分析2013年4月至2017年9月592例II-IV期卵巢癌患者,按调整改良衰弱指数(amFI)分组,amFI≥2为高衰弱。高衰弱患者较少接受腹腔镜评估及肿瘤减灭术,术后并发症及30天内死亡更多,无进展生存期和总生存期更差。
要点
- amFI≥2的高衰弱患者仅17%接受初次肿瘤减灭术,低于amFI=1的26%和amFI=0的34%。
- 高衰弱患者术后并发症发生率64%,高于amFI=1的56%和amFI=0的44%。
- 高衰弱与更差的无进展生存期(p=0.02)和总生存期(p<0.05)相关。
核心结论
- 高衰弱评分患者的术后并发症、无进展生存期和总生存期均更差。
- 量化衰弱可能有助于新诊断晚期卵巢癌患者的临床决策。
研究设计与样本
- 回顾性综述,纳入2013年4月至2017年9月的II-IV期卵巢癌患者。
- 通过腹腔镜对患者进行分诊以确定初次可切除性。
- 计算调整改良衰弱指数(amFI),amFI≥2定义为高衰弱。
- 共592例患者符合纳入标准。
主要发现
- amFI为0、1和≥2的患者分别占57%、29%和14%。
- 接受腹腔镜评估以决定初次手术的患者比例在amFI=0、1和≥2组分别为49%、43%和28%(p=0.004)。
- Fagotti评分≥8的患者比例在amFI=0、1和≥2组分别为58%、48%和34%(p=0.04)。
- 接受初次肿瘤减灭术的患者比例在amFI=0、1和≥2组分别为34%、26%和17%(p=0.02)。
- 接受任何肿瘤减灭术的患者比例在amFI=0、1和≥2组分别为85%、74%和59%(p<0.001)。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: To assess the impact of frailty in patients with ovarian cancer on surgical procedures and outcomes. METHODS: A retrospective review of patients with stage II-IV ovarian cancer from April 2013 to September 2017 was performed. Patients were triaged by laparoscopy to determine primary resectability. The adjusted modified frailty index score (amFI) was calculated and amFI ≥2 classified as high frailty. Clinical outcomes, progression free survival (PFS) and overall survival (OS) were estimated. RESULTS: 592 patients met inclusion criteria; amFI of 0, 1 and ≥ 2 was noted in 57%, 29%, and 14%, respectively. Patients with high frailty were less likely to be offered laparoscopic assessment for primary surgery (49% v. 43% v. 28% for amFI = 0, 1, and ≥ 2, p = 0.004), and more likely to have a Fagotti score ≥ 8 (58%, 48%, and 34%, p = 0.04). Only 17% of the high frailty cohort had primary tumor reductive surgery compared to 26% and 34% in patients with amFI = 1 and amFI = 0 (p = 0.02). Furthermore, patients with higher amFI were less likely to undergo any tumor reductive surgery (85% v. 74% v. 59%, p < 0.001). Postoperative complications were more frequent in patients with higher amFI (44% v. 56% v. 64%, p = 0.01). Death within thirty days of treatment initiation was significantly higher in patients with high frailty (0.4% v. 2% v. 9%, p = 0.005). In multivariate analysis, high frailty was associated with worse PFS (p = 0.02) and OS (p < 0.05). CONCLUSIONS: Postoperative morbidity, PFS, and OS were worse in patients with high frailty scores. Quantification of frailty may be useful for clinical decision making in patients with newly diagnosed advanced ovarian cancer.
引用
- Handley KF, Sood AK, Molin GZD, et al. Frailty repels the knife: The impact of frailty index on surgical intervention and outcomes. Gynecol Oncol. 2022. PMID: 35599168. doi:10.1016/j.ygyno.2022.05.009
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。